# Medpace Holdings, Inc.: overview

MEDP · Nasdaq · CIK 1668397 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/medp.md) · [Financials](/companies/medp/financials.md) · [Filings](/companies/medp/filings.md) · [Insiders](/companies/medp/insiders.md)

Latest reported revenue: [$716.0m](/filings/0001668397-26-000036.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 22, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001668397-26-000036).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [537 d](/filings/0001668397-26-000006.md) | [559](/filings/0001668397-26-000019.md) | [603](/filings/0001668397-26-000025.md) | [660](/filings/0001668397-26-000036.md) | [708 d](/filings/0001668397-26-000006.md) | [707](/filings/0001668397-26-000019.md) | [707](/filings/0001668397-26-000025.md) | [716](/filings/0001668397-26-000036.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [23.4% d](/filings/0001668397-26-000006.md) | [20.3%](/filings/0001668397-26-000019.md) | [20.9%](/filings/0001668397-26-000025.md) | [21.5%](/filings/0001668397-26-000036.md) | [21.6% d](/filings/0001668397-26-000006.md) | [20.0%](/filings/0001668397-26-000019.md) | [20.8%](/filings/0001668397-26-000025.md) | [23.1%](/filings/0001668397-26-000036.md) |
| Net margin | % | [21.8% d](/filings/0001668397-26-000006.md) | [20.5%](/filings/0001668397-26-000036.md) | [15.0%](/filings/0001668397-26-000036.md) | [16.8%](/filings/0001668397-26-000036.md) | [19.1% d](/filings/0001668397-26-000006.md) | [17.5%](/filings/0001668397-26-000036.md) | [17.2%](/filings/0001668397-26-000036.md) | [19.2%](/filings/0001668397-26-000036.md) |
| Diluted EPS | $ per share | not reported | [3.67](/filings/0001668397-26-000019.md) | [3.10](/filings/0001668397-26-000025.md) | [3.86](/filings/0001668397-26-000036.md) | not reported | [4.28](/filings/0001668397-26-000019.md) | [4.25](/filings/0001668397-26-000025.md) | [4.84](/filings/0001668397-26-000036.md) |
| Free cash flow | $m | [183 d](/filings/0001668397-26-000006.md) | [116](/filings/0001668397-26-000019.md) | [142 d](/filings/0001668397-26-000025.md) | [235 d](/filings/0001668397-26-000036.md) | [188 d](/filings/0001668397-26-000006.md) | [145](/filings/0001668397-26-000019.md) | [138 d](/filings/0001668397-26-000025.md) | [196 d](/filings/0001668397-26-000036.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,142](/filings/0001668397-24-000013.md) | [1,460](/filings/0001668397-25-000017.md) | [1,886](/filings/0001668397-26-000006.md) | [2,109](/filings/0001668397-26-000006.md) | [2,530](/filings/0001668397-26-000006.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [17.4%](/filings/0001668397-24-000013.md) | [19.1%](/filings/0001668397-25-000017.md) | [17.9%](/filings/0001668397-26-000006.md) | [21.2%](/filings/0001668397-26-000006.md) | [21.1%](/filings/0001668397-26-000006.md) |
| Net margin | % | [15.9%](/filings/0001668397-24-000013.md) | [16.8%](/filings/0001668397-25-000017.md) | [15.0%](/filings/0001668397-26-000006.md) | [19.2%](/filings/0001668397-26-000006.md) | [17.8%](/filings/0001668397-26-000006.md) |
| Diluted EPS | $ per share | [4.81](/filings/0001668397-24-000013.md) | [7.28](/filings/0001668397-25-000017.md) | [8.88](/filings/0001668397-26-000006.md) | [12.63](/filings/0001668397-26-000006.md) | [15.28](/filings/0001668397-26-000006.md) |
| Free cash flow | $m | [235](/filings/0001668397-24-000013.md) | [351](/filings/0001668397-25-000017.md) | [397](/filings/0001668397-26-000006.md) | [572](/filings/0001668397-26-000006.md) | [682](/filings/0001668397-26-000006.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/medp/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Burwig Susan E](/insiders/1677418.md) | Exec. VP, Operations, Officer | Sale (S) | 3,940 | $677.00 | $2.7m | [Form 4](/filings/0001677418-26-000018.md) |
| 2026-10-26 | [Burwig Susan E](/insiders/1677418.md) | Exec. VP, Operations, Officer | Sale (S) | 16,060 | $677.00 | $10.9m | [Form 4](/filings/0001677418-26-000018.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.32bn | 2,498,248 |  | Added +27,808 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $677.3m | 1,278,935 |  | Reduced −74,902 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $600.2m | 1,133,357 |  | Added +11,668 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $543.8m | 1,026,820 |  | Added +15,749 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $376.5m | 710,895 |  | Added +28,666 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $376.3m | 710,465 |  | Reduced −34,641 |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $337.1m | 636,595 |  | Reduced −137,336 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $306.8m | 579,241 |  | Added +1,667 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $250.6m | 473,211 |  | Reduced −29,980 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $227.2m | 429,012 |  | Added +33,243 |

## Recent filings

[All 929 filings](/companies/medp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 16:02 ET | [10-Q](/filings/0001668397-26-000036.md) | Quarterly report, period 2026-09-30 | 0001668397-26-000036 |
| 2026-10-21 | 16:15 ET | [8-K](/filings/0001668397-26-000034.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001668397-26-000034 |
| 2026-09-28 | 19:15 ET | [SCHEDULE 13D/A](/filings/0001193125-26-405684.md) | Ownership report, active investor, amended | 0001193125-26-405684 |
| 2026-07-23 | 16:03 ET | [10-Q](/filings/0001668397-26-000025.md) | Quarterly report, period 2026-06-30 | 0001668397-26-000025 |
| 2026-07-22 | 16:15 ET | [8-K](/filings/0001668397-26-000023.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001668397-26-000023 |
| 2026-06-04 | 16:06 ET | [8-K](/filings/0001193125-26-257387.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-257387 |
| 2026-05-19 | 14:43 ET | [8-K](/filings/0001193125-26-230425.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-230425 |
| 2026-04-23 | 16:03 ET | [10-Q](/filings/0001668397-26-000019.md) | Quarterly report, period 2026-03-31 | 0001668397-26-000019 |
| 2026-04-22 | 16:15 ET | [8-K](/filings/0001668397-26-000017.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001668397-26-000017 |
| 2026-04-01 | 16:38 ET | [DEF 14A](/filings/0001668397-26-000012.md) | Proxy statement, period 2026-05-15 | 0001668397-26-000012 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001668397-26-000006.md), filed Feb 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1668397
- Tickers: MEDP
- Exchange: Nasdaq
- SIC code: 8731 Services-Commercial Physical & Biological Research
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 15:38 ET. No prices; not investment advice.